The global electrophysiology devices market size was valued at USD 6.1 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 11.16% from 2023 to 2030. Increasing use of Electrophysiology (EP) test in the treatment and diagnosis of heart diseases, such as atrial fibrillation, growing demand for devices for cardiac rhythm management for constant monitoring, and increasing application of these devices in out-of-hospital settings, are propelling the industry growth. The prevalence of heart failure, cardiac arrest, and atrial fibrillation among millennials is rising due to sedentary lifestyles, smoking, excessive alcohol consumption, and others. According to the CDC, approximately 12.1 million Americans will be suffering from atrial fibrillation by 2030.
In addition, European people are more prone to atrial fibrillation than African Americans. As per the European Society of Cardiology, sudden cardiac arrest due to abnormal heart rhythm is one of the major reasons for death in western countries. It affects approximately 1 in 1,000 inhabitants per year. Electrophysiology devices are cardiology specialty equipment used mainly in the diagnosis and treatment of cardiac arrhythmias. Thus, the increasing prevalence of heart diseases is augmenting the market growth. EP has facilitated the use of mobile cardiac telemetry and ambulatory ECG monitoring. Technological advancements, such as remote monitoring of implantable cardiac devices,data storage in the cloud, and the incorporation of wireless transmission, are expected to propel market growth.
Pandemic Impact |
Post COVID Outlook |
The COVID-19 pandemic severely impacted industry growth. Cancellation and postponement of non-urgent EP procedures resulted in a sharp decline in sales. According to a study published in NCBI, elective EP procedures levels were less than 5% of normal values at 3 centers in the U.K., China, and Italy |
The market is now stabilizing owing to the adoption of digital healthcare. Ease in restrictions, resuming of hospital services, and gradual increase in patient volume is favoring the overall demand The revenues of the companies have surged as compared to the pandemic times. For instance, net sales of Boston Scientific Corp.’s electrophysiology segment reported a growth of 27.2% in 2021 |
Owing to the decline in demand, manufacturers reported huge revenue losses. For instance, Abbott witnessed a decline of 8.3% in electrophysiology products revenues in 2020 compared to 2019 |
Adoption of ambulatory monitoring devices for the monitoring and diagnosis of arrhythmia and related complications paved the way to overcome the short-term negative impact of the pandemic |
For instance, in May 2019, Biosense Webster launched the CARTONET platform, a novel cloud-based network that interconnects myriad devices and transfers the data that is utilized during the practice. It aids the healthcare providers to access the patient’s information, such as 3D images and videos, which are obtained during the ablation procedures. In recent years, the shift of patients towards minimally invasive surgeries has increased. The introduction of minimally invasive technologies, such as cryoablation, laser ablation, ultrasound ablation, and advanced mapping technologies, is also expected to bode well with the industry. For instance, in February 2022, Medtronic received U.S. FDA approval for the Freezor & Freezor Xtra, Cardiac Cryoablation Focal Catheters for the treatment of Atrioventricular Nodal Reentrant Tachycardia (AVNRT) in pediatric patients.
Based on application, the industry is classified into treatment devices and diagnostic devices. The diagnostic devices segment accounted for the largest share of more than 52.1% of the global revenue in 2022. High usage rates of cardiac monitors as a standard diagnostic and monitoring tool for arrhythmias and rising adoption of ambulatory monitoring equipment are factors responsible for the dominant share of the segment. EP diagnostic devices include Holter monitors, Electrocardiograph (ECG), diagnostic catheters, mapping & imaging systems, and insertable cardiac monitors. The growing use of these equipment in interventional medical procedures, such as catheter placement, and the introduction of portable & digital systems are expected to drive segment growth during the forecast period.
In November 2021, Koninklijke Philips N.V. announced the acquisition of Cardiologs, a medical technology firm based in France. The acquisition will expand the cardiac diagnostics and monitoring business of Philips with the company’s AI and cloud technology. Increasing investment to incorporate new technologies is likely to favor segment growth. The treatment devices segment is anticipated to register the maximum CAGR of 11.62% during the forecast period. The treatment devices segment comprises Implantable Cardioverter Defibrillators (ICD), Automated External Defibrillators (AEDs), pacemakers, and catheters. The growing incidence of atrial fibrillation & arrhythmia, rising adoption of cardiac implantable electronic devices, and healthcare approvals are favoring the segment growth. For instance, in January 2022, Abbott received approval for EnSite X EP System with EnSite omnipolar technology from the U.S. FDA for the treatment of cardiac arrhythmias.
In terms of indication, the electrophysiology devices market is bifurcated into Atrial Fibrillation (AF), Supraventricular Tachycardia (SVT), Atrioventricular Nodal Re-entry Tachycardia (AVNRT), Wolff-Parkinson-White Syndrome (WPW), bradycardia, and others. The atrial fibrillation segment dominated the market in 2022 and accounted for the maximum revenue share of more than 32.3%. It is the most common type of arrhythmia associated with a high risk of stroke and blood clotting. According to the British Heart Association estimates in 2022, approximately 1.5 million of the U.K. population suffers from atrial fibrillation. In addition, an expected 270,000 individuals aged 65 years and above have undiagnosed atrial fibrillation in the country. The high prevalence of the disease is responsible for the prominent share of the segment.
In recent years, innovative smartphone applications have been introduced for arrhythmic patients that can connect them with healthcare professionals. Moreover, hospitals and clinical settings are taking initiatives to involve arrhythmia care in their treatment routine. In May 2018, UNC AFib Care Network launched a new clinic for atrial fibrillation patients - AFib Integrated Care Clinic. The Supraventricular Tachycardia (SVT) segment is anticipated to witness remarkable growth of 12.27% during the forecast period. Increasing research to develop the treatment for SVT, rising healthcare cost, and an increasing number of emergency admissions are likely to favor the segment growth. According to a study published in the National Library of Medicine, SVT has a prevalence of 2.25 cases per 1,000 in the general population, with an incidence of 35 cases per 100,000 patients.
The hospitals segment accounted for the highest share of 54.1% of the global revenue in 2022. The adoption of technologically advanced cardiac rhythm management and EP systems by interventional cardiologists and the rising burden of Cardiovascular Disease(CVD) is responsible for the dominant share of the segment. As per a study published in April 2018, daily short-term rhythm strip recordings identified an increase of 13.0% in the elderly population hospitalized for atrial fibrillation, leading to an overall prevalence of 46.0% in hospitalized patients. The ASCs segment is projected to exhibit considerable growth with a CAGR of 11.81% during the forecast period.
A shift towards minimally invasive outpatient procedures and significant cost savings are augmenting the growth of the segment. For instance, a study by Health Affairs revealed that ASC procedures are cost- and time-effective. It takes around 25% less time as compared to the hospitals with USD 360 to 1,000 savings per patient owing to the less fixed costs. Furthermore, government initiatives to reduce the cost of treatment and favor reimbursement policies are propelling the segment growth. The Centers for Medicare & Medicaid Services (CMS) extended ambulatory surgical coverage for cardiac interventional procedures, such as pacemaker implants, endovenous ablation, and catheterization procedures.
North America dominated the industry in 2021 and accounted for the maximum share of more than 37.5% of the global revenue owing to the high cases of heart failure, cardiac arrest, and cardiac arrhythmia. The presence of sophisticated healthcare infrastructure and favorable reimbursement policies are expected to drive the region’s growth during the forecast period.
The market in Asia Pacific is estimated to witness the fastest growth rate during the forecast period. The high geriatric population, growing risk of heart diseases, and unmet clinical needs are primary factors driving the region’s growth.
Furthermore, improving healthcare infrastructure, increasing patient awareness, and rising healthcare expenditure levels in the region are expected to assist manufacturers in capitalizing on these available opportunities. Rapid developments in healthcare infrastructure and an increase in disposable income in emerging economies, such as India and China, are projected to boost the demand for EP systems. Moreover, technological advancements in the region are another factor contributing to the market growth. For instance, in August 2021, Shanghai Microport EP Medtech Co., Ltd. collaborated with Stereotaxis, Inc. Under the terms of the agreement, Microport EP will be distributing Robotic Magnetic Navigation technology for EP in China.
The market is highly competitive with companies adhering to new product development and extensive R&D investments as sustainability strategies. Globally, companies are following an inorganic growth strategy for strengthening product portfolios and establishing a foothold in the industry. For instance, in February 2022, Boston Scientific Corp. completed the acquisition of Baylis Medical Company Inc., a company specialized in offering an advanced transseptal solution for catheter-based procedures for the left side of the heart.
The untapped emerging markets in Asian countries like India and China offer a great opportunity to investors for expansion in the region. For instance, in June 2021, Medtronic launched the Micra AV in India. It is a completely self-contained, compact pacemaker that provides innovative pacing technology to AV block patients via minimally invasive methods. The device can detect activities in the atria without the aid of another device in the upper chamber of the heart. Some of the companies operating in the global electrophysiology devices market are:
Boston Scientific Corp.
Medtronic
Abbott
Biosense Webster (Johnson & Johnson Services, Inc.)
Biotronik
General Electric Company
Siemens Healthcare AG
MicroPort Scientific Corporation
Koninklijke Philips N.V.
Report Attribute |
Details |
Market size value in 2023 |
USD 6.6 billion |
Revenue forecast in 2030 |
USD 13.9 million |
Growth rate |
CAGR of 11.16% from 2022 to 2030 |
Base year for estimation |
2022 |
Historical data |
2016 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, indication, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Mexico; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Boston Scientific Corp.; Medtronic; Abbott; Biosense Webster (Johnson & Johnson Services, Inc.); Biotronik; General Electric Company; Siemens Healthcare AG; MicroPort Scientific Corporation; Koninklijke Philips N.V. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2016 to 2030. For the purpose of this study, Grand View Research has segmented the global electrophysiology devices market report on the basis of application, indication, end-use, and region:
Application Outlook (Revenue, USD Million; 2018 - 2030)
Treatment Devices
Implantable Cardioverter Defibrillators (ICDs)
Automated External defibrillators (AEDs)
Pacemakers
CRT-P
CRT-D
Catheters
Others
Diagnostic Devices
Holter Monitoring Devices
Diagnostic Electrophysiology Catheters
Electrocardiograph (ECG)
EP Mapping & Imaging Systems
Insertable Cardiac Monitors (ICM)
Others
Indication Outlook (Revenue, USD Million; 2018 - 2030)
Atrial Fibrillation (AF)
Supraventricular Tachycardia
Atrioventricular Nodal Re-entry Tachycardia (AVNRT)
Wolff-Parkinson-White Syndrome (WPW)
Bradycardia
Other
End-Use Outlook (Revenue, USD Million; 2018 - 2030)
Hospitals
Ambulatory Surgical Centers
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Mexico
Brazil
Argentina
Middle East & Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global electrophysiology devices market size was estimated at USD 6.1 billion in 2022 and is expected to reach USD 6.6 billion in 2023
b. The global electrophysiology devices market is expected to grow at a compound annual growth rate of 11.16% from 2023 to 2030 to reach USD 13.9 billion by 2030
b. North America dominated the electrophysiology devices market with a share of 37.5% in 2022. This is attributable to the high patient base of cardiac arrhythmia resulting from unhealthy lifestyle habits and favorable reimbursement policies in the region
b. Some key players operating in the electrophysiology devices market include Boston Scientific Corporation, Medtronic, Abbott, Biosense Webster, Inc. (Johnson & Johnson), Biotronik SE & Co. KG., GE Healthcare, and Siemens Healthineers AG
b. Key factors that are driving the electrophysiology devices market growth include growing demand for cardiac rhythm management devices for continuous monitoring and the increasing use of these devices in out-of-hospital settings
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.